Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Ennis (EBF) Reports In-Line Q1 EPS
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
